CTOs on the Move

Techcyte

www.techcyte.com

 
Partnering with Labs and Clinics Techcyte creates AI-powered digital diagnostic tests to assist labs and clinics with a more efficient diagnostic process. Were working closely with lab professionals and pathologists to make quantum leaps in efficiency...
  • Number of Employees: 25-100
  • Annual Revenue: $10-50 Million
  • www.techcyte.com
  • 1426, East 750 North Street
    Orem, UT USA 84097
  • Phone: 888.878.3249

Executives

Name Title Contact Details

Similar Companies

Firefly MSP

Firefly MSP is a friendly managed service provider of technology solutions. We are IT partners for your IT needs.

Mini-Computer Business

Mini-Computer Business is a Huntsville, AL-based company in the Software and Internet sector.

GoPivot

GoPivot Solutions is a mobile-first, points-based rewards platform that helps employers motivate, recognize, and engage with employees to improve health and wellness, reduce OSHA incidents, or drive any other new initiative.

data.ai

data.ai (formerly App Annie) is a Unified Data AI company that combines consumer and market data to provide insights powered by artificial intelligence. They serve enterprise clients to create winning digital experiences for their customers.

Kapost

Juventas Therapeutics is a private clinical-stage company developing novel therapies for ischemic cardiovascular disease. The company`s lead product` JVS-100` is a non-viral plasmid that encodes for stromal cell-derived factor-1 (SDF-1). SDF-1 has been shown to significantly increase end-organ function following tissue injury by promoting cell survival` recruiting endogenous stem cells to the damaged region` and promoting new blood vessel growth. The SDF-1 repair pathway is well conserved throughout end-organ systems providing the opportunity to impact a broad range of diseases. Target cardiovascular clinical indications address large markets with high unmet medical need and significant market potential. Juventas is currently enrolling multiple clinical trials to test therapy efficacy in heart failure and critical limb ischemia patients.